Cargando…

One-Year Open-Label Study of Entacapone in Patients with Advanced Parkinson Disease

BACKGROUND AND PURPOSE: A carboxy-O-methyl transferase inhibitor entacapone has been introduced as an adjuvant drug for Parkinson disease (PD) patients. Although clinical trials reported beneficial role of entacapone, a long-term trial over 3 years failed to show significant effect. The goals of thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Tae-Beom, Im, Joo-Hyuk, Lee, Myoung Chong, Kim, Jae Woo, Lee, Won Yong, Jeon, Beom S.
Formato:	Texto
Lenguaje:	English
Publicado:	Korean Neurological Association 2007
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686863/ https://www.ncbi.nlm.nih.gov/pubmed/19513296 http://dx.doi.org/10.3988/jcn.2007.3.2.82

Ejemplares similares

Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
por: Kocer, Bilge, et al.
Publicado: (2016)

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
por: Park, Kye Won, et al.
Publicado: (2020)

Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
por: Kim, Han-Joon, et al.
Publicado: (2011)

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
por: Poulopoulos, Markos, et al.
Publicado: (2010)

Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
por: Kim, Jong-Min, et al.
Publicado: (2015)

Entacapone promotes hippocampal neurogenesis in mice
por: Yoo, Dae Young, et al.
Publicado: (2020)

Lymphocytic colitis associated with entacapone
por: Rodrigues, David M., et al.
Publicado: (2022)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
por: Müller, Thomas
Publicado: (2009)

Correction to “Lymphocytic colitis associated with entacapone”
Publicado: (2022)

Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone
por: Vokurka, Petr, et al.
Publicado: (2020)

Pumpentherapie bei fortgeschrittenem Parkinson-Syndrom: Charakterisierung des Intestinalgels Levodopa-Entacapon-Carbidopa
por: H. Jost, Wolfgang, et al.
Publicado: (2022)

Colite lymphocytaire associée à l’entacapone
por: Rodrigues, David M., et al.
Publicado: (2023)

Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance
por: Nyholm, Dag, et al.
Publicado: (2022)

A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson’s Disease
por: Fu, Shih-Chen, et al.
Publicado: (2022)

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo(®))
por: Solla, Paolo, et al.
Publicado: (2010)

Entacapone Reduces Cortical Activation in Parkinson's Disease with Wearing-Off: A f-MRI Study
por: Tambasco, Nicola, et al.
Publicado: (2014)

Population pharmacokinetics of levodopa gel infusion in Parkinson’s disease: effects of entacapone infusion and genetic polymorphism
por: Senek, M., et al.
Publicado: (2020)

Entacapone Treatment Modulates Hippocampal Proteins Related to Synaptic Vehicle Trafficking
por: Yoo, Dae Young, et al.
Publicado: (2020)

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: Brooks, David J
Publicado: (2008)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo(®) 200) in the treatment of Parkinson’s disease: a case series
por: Sethi, Kapil D, et al.
Publicado: (2009)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
por: Öthman, Mezin, et al.
Publicado: (2021)

Gravitational syncope induced by rising elevators in a Parkinson’s disease patient
por: Sohn, Sun-Woo, et al.
Publicado: (2023)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation
por: Yi, Zhan-Miao, et al.
Publicado: (2018)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

Dropped Head Syndrome after Minor Trauma in a Patient with Levosulpiride-Aggravated Vascular Parkinsonism
por: Cho, Soo Hyun, et al.
Publicado: (2016)

Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
por: Kim, Aryun, et al.
Publicado: (2018)

The role of quercetin on the survival of neuron-like PC12 cells and the expression of α-synuclein
por: Ahn, Tae-Beom, et al.
Publicado: (2015)

Translation and Validation of the Korean Version of the 39-Item Parkinson's Disease Questionnaire
por: Kwon, Do-Young, et al.
Publicado: (2013)

Validation of the Korean-Version of the Nonmotor Symptoms Scale for Parkinson's Disease
por: Koh, Seong-Beom, et al.
Publicado: (2012)

Increased dose of carbidopa with levodopa and entacapone improves “off” time in a randomized trial
por: Trenkwalder, Claudia, et al.
Publicado: (2019)

Clinical Analysis of Blepharospasm and Apraxia of Eyelid Opening in Patients with Parkinsonism
por: Yoon, Won Tae, et al.
Publicado: (2005)

Apparently Ipsilateral Parkinsonism in a Patient with Chronic Subdural Hematoma
por: Roh, Tae Hwan, et al.
Publicado: (2012)

Familial Parkinson's Disease/Parkinsonism
por: Tomiyama, Hiroyuki, et al.
Publicado: (2015)

In vitro and in vivo characterization of Entacapone-loaded nanostructured lipid carriers developed by quality-by-design approach
por: Agrawal, Yogeeta, et al.
Publicado: (2022)

Efficacy and Safety of Cream Containing Climbazole/Piroctone Olamine for Facial Seborrheic Dermatitis: A Single-Center, Open-Label Split-Face Clinical Study
por: Youn, Hae Jeong, et al.
Publicado: (2016)

Hypothesis: Somatic Mosaicism and Parkinson Disease
por: Kim, Han-Joon, et al.
Publicado: (2014)

Patients and Their Caregivers’ Burdens for Parkinson’s Disease in Korea
por: Baik, Jong Sam, et al.
Publicado: (2017)

Parkinsonism in Spinocerebellar Ataxia
por: Park, Hyeyoung, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cmpkgs58enjeb58ibsqgflgo40